Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Organisation › Details

Cosmo Pharmaceuticals (Group)

Cosmo is a specialty pharmaceutical company that aims to become a global leader in the field of optimized therapies for selected gastrointestinal disorders and endoscopic procedures. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for IBD (inflammatory bowel disease), such as ulcerative colitis and Crohn’s disease, and colon infections. In addition, the company has developed a medical device for polyp excision and is developing a product for the detection of colon cancer and has a large shareholding in Cassiopea SpA, a clinical-stage specialty pharmaceutical company focusing on developing and commercializing innovative and differentiated medical dermatology products. Cosmo’s MMX® products that have reached the market are Lialda®/Mezavant®/Mesavancol®, a treatment for IBD that is licensed globally to Nogra and Shire Limited and Uceris®, the first glucocorticosteroid indicated for the induction of remission in active, mild to moderate ulcerative colitis, licensed in the U.S. to Santarus/Salix/Valeant and in the rest of the world to Ferring. Cosmo’s proprietary MMX® technology is at the core of the company’s product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (good manufacturing practice) facilities in Lainate, Italy. The technology is designed to deliver active ingredients in a targeted manner in colon. *


Period Start 2005-05-01 existent
Products Industry gastrointestinal drug
  Industry 2 MMX Multi Matrix System™ drug delivery technology
Persons Person Della Chà, Alessandro (Cosmo Pharmaceuticals 201507 CEO)
  Person 2 Donnelly, Niall (Cosmo Pharmaceuticals 201607 CFO)
Region Region Lainate (MI)
  Country Italy
  Street 1 Via Cristoforo Colombo
  City 20020 Lainate (MI)
  Tel +39-02-9333-7614
    Address record changed: 2018-07-24
Basic data Employees D: 101 to 500 (2016-12-31)
  Currency EUR
  Annual sales 67,664,000 (revenue, total, consolidated (2016) 2016-12-31)
  Profit 19,340,000 (2016-12-31)
  Cash 117,649,000 (2016-12-31)
    * Document for �About Section�: Paion AG. (6/24/16). "Press Release: Paion Grants Cosmo Pharmaceuticals Remimazolam License in the U.S. and Cosmo Becomes Largest Shareholder of Paion AG". Aachen.
Record changed: 2017-03-28


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Cosmo Pharmaceuticals (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top